Teacher Retirement System of Texas Has $39.99 Million Stake in Gilead Sciences, Inc. $GILD

Teacher Retirement System of Texas decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 360,644 shares of the biopharmaceutical company’s stock after selling 20,777 shares during the period. Teacher Retirement System of Texas’ holdings in Gilead Sciences were worth $39,985,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in GILD. One Wealth Advisors LLC increased its holdings in Gilead Sciences by 34.8% in the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after buying an additional 2,364 shares during the last quarter. Ariel Investments LLC increased its holdings in Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock worth $48,229,000 after buying an additional 30,630 shares during the last quarter. Golden State Wealth Management LLC increased its holdings in Gilead Sciences by 14.5% in the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 109 shares during the last quarter. Covea Finance boosted its position in Gilead Sciences by 69.5% during the second quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company’s stock worth $5,732,000 after purchasing an additional 21,200 shares during the period. Finally, Swedbank AB boosted its position in Gilead Sciences by 0.8% during the first quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company’s stock worth $237,393,000 after purchasing an additional 16,663 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. BMO Capital Markets upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. TD Cowen upped their target price on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Finally, Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $122.61.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the transaction, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 61,500 shares of company stock valued at $7,142,140 over the last ninety days. 0.27% of the stock is owned by company insiders.

Gilead Sciences Stock Down 0.4%

Shares of GILD stock opened at $120.47 on Tuesday. The stock has a market cap of $149.48 billion, a P/E ratio of 24.00, a price-to-earnings-growth ratio of 0.83 and a beta of 0.34. Gilead Sciences, Inc. has a one year low of $86.08 and a one year high of $124.61. The stock has a fifty day moving average price of $115.52 and a 200 day moving average price of $111.21. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.